Asset
ADG-106
Adagene Inc. American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04501276 | phase1 | completed | 2020-09-23 | 2024-01-17 | Adagene Inc | A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients |
| NCT04775680 | phase1_2 | terminated | 2021-03-11 | 2023-02-09 | Adagene (Suzhou) Limited | Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma |
| NCT03802955 | phase1 | completed | 2018-12-20 | 2021-11-01 | Adagene (Suzhou) Limited | Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma |
| NCT03707093 | phase1 | completed | 2018-09-17 | 2022-01-24 | Adagene Inc | Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma |
FDA applications (0)
This company has no applications containing this asset.